Mr. Christopher Barnes reports

SERNOVA ANNOUNCES AGM VOTING RESULTS

Sernova Corp. is releasing results from its annual general meeting of shareholders held virtually via live audio webcast, on April 30, 2024.

At the meeting, a total of 88,316,160 common shares were voted, representing 29.11 per cent of the votes attached to all outstanding common shares as of the record date. The voting results were as follows:

Director          % of votes for    % of votes against

Cynthia Pussinen          95.62%                 4.38%             
James T. Parsons          98.63%                 1.37%             
Dr. Steven Sangha         96.43%                 3.57%             
Brett A. Whalen           73.91%                26.09%

Accordingly, Cynthia Pussinen, James T. Parsons, Dr. Steven Sangha and Brett A. Whalen were elected to the board of directors for the ensuing year. In addition, Bernd Muehlenweg was appointed to the board of directors following the AGM. Bertram Plettenberg resigned from the board of directors prior to the AGM and did not stand for election at the AGM.

Shareholders also approved (with 99.79 per cent of the votes approving) the reappointment of KPMG LLP, chartered professional accountants, as the company's auditor for the ensuing year, and approved (with 82.57 per cent of the votes approving) the amendments to the option plan and DSU plan and the increase in the maximum number of common shares reserved for issuance.

About Sernova Corp.

Sernova is a clinical-stage biotechnology company that is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease and blood disorders that include hemophilia A. Sernova is currently focused on developing a functional cure for insulin-dependent diabetes with its lead technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells.

We seek Safe Harbor.